FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2153400781> ?p ?o ?g. }

• W2153400781 endingPage "27" @default.
• W2153400781 startingPage "20" @default.
• W2153400781 abstract "Pharmacogenomic applications in oncology offer significant promise, but the clinical and economic implications remain unclear. The objective of this study was to evaluate the potential cost-utility of implementing epidermal growth factor receptor (EGFR) testing before initiating second-line therapy for advanced refractory non-small-cell lung cancer (NSCLC).We developed a decision analytic model to evaluate the cost-utility of EGFR protein expression or gene copy number testing compared to standard care with erlotinib in refractory advanced NSCLC patients. Costs and utilities were obtained from publicly available sources. We performed sensitivity analyses to evaluate uncertainty in the results.The quality-adjusted life expectancies for erlotinib, EGFR protein expression testing, and gene copy number testing were: 0.44, 0.48, and 0.50 quality-adjusted life years (QALYs); and the costs were: $57,238, $63,512, and $66,447, respectively. The most cost-effective testing option, EGFR gene copy number testing, produced an incremental cost-effectiveness ratio of $162,018/QALY compared to no testing (erlotinib). The results were most sensitive to the survival estimates, health state utilities, and cost of disease progression. In the probabilistic sensitivity analyses, erlotinib without testing was the optimal treatment strategy until the $150,000/QALY willingness-to-pay threshold, after which gene copy testing was optimal. The discounted expected value of perfect information at a $100,000/QALY threshold in the USA over 5 years was $31.4 million.The study results suggest that EGFR pharmacogenomic testing has the potential to improve quality-adjusted life expectancy in the treatment of refractory NSCLC by a clinically meaningful margin at a value commensurate with the approved therapies in this setting. Additional research in this area is warranted." @default.
• W2153400781 created "2016-06-24" @default.
• W2153400781 creator A5046985026 @default.
• W2153400781 creator A5060938706 @default.
• W2153400781 creator A5068073076 @default.
• W2153400781 creator A5085042140 @default.
• W2153400781 date "2009-01-01" @default.
• W2153400781 modified "2023-10-18" @default.
• W2153400781 title "The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Cancer" @default.
• W2153400781 cites W1252407659 @default.
• W2153400781 cites W1839238860 @default.
• W2153400781 cites W1964321121 @default.
• W2153400781 cites W1970232026 @default.
• W2153400781 cites W1970476748 @default.
• W2153400781 cites W1971681479 @default.
• W2153400781 cites W1977663202 @default.
• W2153400781 cites W1988442083 @default.
• W2153400781 cites W1994747360 @default.
• W2153400781 cites W2002373091 @default.
• W2153400781 cites W2012563788 @default.
• W2153400781 cites W2012922023 @default.
• W2153400781 cites W2020408727 @default.
• W2153400781 cites W2030154801 @default.
• W2153400781 cites W2037667818 @default.
• W2153400781 cites W2042793526 @default.
• W2153400781 cites W2048634696 @default.
• W2153400781 cites W2052676662 @default.
• W2153400781 cites W2056535857 @default.
• W2153400781 cites W2083149063 @default.
• W2153400781 cites W2087238575 @default.
• W2153400781 cites W2101055110 @default.
• W2153400781 cites W2107304950 @default.
• W2153400781 cites W2107977972 @default.
• W2153400781 cites W2114060414 @default.
• W2153400781 cites W2121277505 @default.
• W2153400781 cites W2124122050 @default.
• W2153400781 cites W2130652363 @default.
• W2153400781 cites W2134667653 @default.
• W2153400781 cites W2138297714 @default.
• W2153400781 cites W2138604360 @default.
• W2153400781 cites W2141393790 @default.
• W2153400781 cites W2142195688 @default.
• W2153400781 cites W2148783573 @default.
• W2153400781 cites W2149743048 @default.
• W2153400781 cites W2150923784 @default.
• W2153400781 cites W2155946891 @default.
• W2153400781 cites W2160866033 @default.
• W2153400781 cites W2177459756 @default.
• W2153400781 cites W2266927457 @default.
• W2153400781 cites W4256695226 @default.
• W2153400781 cites W79301660 @default.
• W2153400781 doi "https://doi.org/10.1111/j.1524-4733.2008.00415.x" @default.
• W2153400781 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18647257" @default.
• W2153400781 hasPublicationYear "2009" @default.
• W2153400781 type Work @default.
• W2153400781 sameAs 2153400781 @default.
• W2153400781 citedByCount "80" @default.
• W2153400781 countsByYear W21534007812012 @default.
• W2153400781 countsByYear W21534007812013 @default.
• W2153400781 countsByYear W21534007812014 @default.
• W2153400781 countsByYear W21534007812015 @default.
• W2153400781 countsByYear W21534007812016 @default.
• W2153400781 countsByYear W21534007812017 @default.
• W2153400781 countsByYear W21534007812018 @default.
• W2153400781 countsByYear W21534007812019 @default.
• W2153400781 countsByYear W21534007812020 @default.
• W2153400781 countsByYear W21534007812021 @default.
• W2153400781 crossrefType "journal-article" @default.
• W2153400781 hasAuthorship W2153400781A5046985026 @default.
• W2153400781 hasAuthorship W2153400781A5060938706 @default.
• W2153400781 hasAuthorship W2153400781A5068073076 @default.
• W2153400781 hasAuthorship W2153400781A5085042140 @default.
• W2153400781 hasBestOaLocation W21534007811 @default.
• W2153400781 hasConcept C112930515 @default.
• W2153400781 hasConcept C121608353 @default.
• W2153400781 hasConcept C126322002 @default.
• W2153400781 hasConcept C133925201 @default.
• W2153400781 hasConcept C143998085 @default.
• W2153400781 hasConcept C159110408 @default.
• W2153400781 hasConcept C170734499 @default.
• W2153400781 hasConcept C2776256026 @default.
• W2153400781 hasConcept C2778087573 @default.
• W2153400781 hasConcept C2779438470 @default.
• W2153400781 hasConcept C2779951463 @default.
• W2153400781 hasConcept C2908647359 @default.
• W2153400781 hasConcept C3019080777 @default.
• W2153400781 hasConcept C535046627 @default.
• W2153400781 hasConcept C64332521 @default.
• W2153400781 hasConcept C71924100 @default.
• W2153400781 hasConcept C98274493 @default.
• W2153400781 hasConcept C99454951 @default.
• W2153400781 hasConceptScore W2153400781C112930515 @default.
• W2153400781 hasConceptScore W2153400781C121608353 @default.
• W2153400781 hasConceptScore W2153400781C126322002 @default.
• W2153400781 hasConceptScore W2153400781C133925201 @default.
• W2153400781 hasConceptScore W2153400781C143998085 @default.
• W2153400781 hasConceptScore W2153400781C159110408 @default.
• W2153400781 hasConceptScore W2153400781C170734499 @default.

• next